A dynamic model of poliomyelitis outbreaks: Learning from the past to help inform the future

American Journal of Epidemiology

Volumn 162, Issue 4, 2005, Pages 358-372

  Tebbens, Radboud J Duintjer ^a,b   Pallansch, Mark A ^c   Kew, Olen M ^c   Cáceres, Victor M ^d   Sutter, Roland W ^e   Thompson, Kimberly M ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d CENTERS FOR DIS CONTR AND PREV   (United States)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Disease outbreaks; Disease transmission; Models, statistical; Poliomyelitis; Poliovirus; Risk assessment; Vaccination

Indexed keywords

EPIDEMIOLOGICAL PHENOMENA;

ACCURACY; ARTICLE; DISEASE TRANSMISSION; ERADICATION THERAPY; HEALTH CARE POLICY; HUMAN; INCIDENCE; INFECTION RISK; MATHEMATICAL MODEL; POLIOMYELITIS; QUESTIONNAIRE; RISK ASSESSMENT; ADOLESCENT; ADULT; CHILD; DOMINICAN REPUBLIC; EPIDEMIC; EUROPE; INFANT; MIDDLE AGED; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; REVIEW; STATISTICAL MODEL;

POLIOVIRUS;

POLIOMYELITIS VACCINE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; DOMINICAN REPUBLIC; EUROPE; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; INFANT; MIDDLE AGED; MODELS, STATISTICAL; POLIOMYELITIS; POLIOVIRUS VACCINES; RISK ASSESSMENT;

EID: 23944506123     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwi206     Document Type: Article

References (67)

1. World Health Assembly, World Health Organization. Global eradication of poliomyelitis by the year 2000. (Resolution 41.28). Geneva, Switzerland: World Health Organization, 1988.
2. World Health Organization. Global Polio Eradication Initiative: progress 2003. Geneva, Switzerland: World Health Organization, 2004. (Report no. WHO/Polio/01.04).
3. Smith J, Leke R, Adams A, et al. Certification of polio eradication: process and lessons learned. Bull World Health Organ 2004;82:24-9.
4. Sangrujee N, Duintjer Tebbens RJ, Cáceres VM, et al. Policy decision options during the first 5 years following certification of polio eradication. MedGenMed 2003;5:35. (Electronic article).
5. Dowdle WR, Wolff C, Sanders R, et al. Will containment of wild poliovirus in laboratories and inactivated poliovirus vaccine production sites be effective for global certification? Bull World Health Organ 2004;82:59-62.
6. Kew OM, Wright PF, Agol VI, et al. Circulating vaccine-derived polioviruses: current state of knowledge. Bull World Health Organ 2004;82:16-23.
7. Aylward RB, Cochi SL. Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild polio-virus transmission. Bull World Health Organ 2004;82:40-6.
8. Fine PEM, Oblapenko G, Sutter RW. Polio control after certification: major issues outstanding. Bull World Health Organ 2004;82:47-52.
9. Poliomyelitis in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 1997;46.
10. Dowdle WR, Birmingham ME. The biologic principles of poliovirus eradication. J Infect Dis 1997;175(suppl 1):S286-92.
11. Nathanson N, Martin JR. The epidemiology of poliomyelitis: enigmas surrounding its appearance, epidemicity, and disappearance. Am J Epidemiol 1979;110:672-92.
12. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine - live. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia, PA: W B Saunders Company, 2004:651-705.
13. Fine PE, Sutter RW, Orenstein WA. Stopping a polio outbreak in the post-eradication era. Dev Biol (Basel) 2001;105:129-47.
14. Melnick JL. Poliovirus and other enteroviruses. In: Evans AS, Kaslow RA, eds. Viral infections of humans: epidemiology and control. New York, NY: Plenum Medical Book Company, 1997:583-663.
15. Plotkin SA, Vidor E. Poliovirus vaccine - inactivated. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia, PA: W B Saunders Company, 2004:625-49.
16. Ghendon YZ, Sanakoyeva II. Comparison of the resistance of the intestinal tract to poliomyelitis virus (Sabin's strains) in persons after naturally and experimentally acquired immunity. Acta Virol (Praha) 1961;5:265-73.
17. Onorato IM, Modlin JF, McBean MA, et al. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis 1991;163:1-6.
18. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991;13:926-39.
19. Sutter RW, Cáceres VM, Más Lago P. The role of routine immunization in the post-certification era. Bull World Health Organ 2004;82:31-8.
20. Patriarca PA, Sutter RW, Oostvogel PM. Outbreaks of paralytic poliomyelitis, 1976-1995. J Infect Dis 1997;175 (suppl 1):S165-72.
21. Serfling R. Historical review of epidemic theory. Hum Biol 1952;24:145-66.
22. Elveback LR, Fox JP, Ackerman E, et al. An influenza simulation model for immunization studies. Am J Epidemiol 1976;103:152-65.
23. Anderson RM, May RM. Infectious diseases of humans: dynamics and control. New York, NY: Oxford University Press, 1991.
24. Chen CJ, Lin TM, You SL. Epidemiological aspects of a poliomyelitis outbreak in Taiwan, 1982. Ann Acad Med Singapore 1984;13:149-55.
25. Cvjetanovic B, Grab B, Dixon H. Epidemiological models of poliomyelitis and measles and their application in the planning of immunization programmes. Bull World Health Organ 1982;60:405-22.
26. Eichner M, Hadeler KP. Deterministic models for the eradication of poliomyelitis: vaccination with the inactivated (IPV) and attenuated (OPV) polio virus vaccine. Math Biosci 1995;127:149-66.
27. Fine PE, Carneiro IA. Transmissibility and persistence of oral poliovirus vaccine viruses: implications for the Global Poliomyelitis Eradication Initiative. Am J Epidemiol 1999;150:1001-21.
28. Eichner M, Dietz K. Eradication of poliomyelitis: when can one be sure that polio virus transmission has been terminated? Am J Epidemiol 1996;143:816-22.
29. Elveback L, Ackerman E, Gatewood L, et al. Stochastic two-agent epidemic simulation models for a community of families. Am J Epidemiol 1971;93:267-80.
30. Eichner M, Hadeler KP, Dietz K. Stochastic models for the eradication of poliomyelitis: minimum population size for polio virus persistence. In: Isham V, Medley GF, eds. Models for infectious human diseases: their structure and relation to data. New York, NY: Cambridge University Press, 1996:315-27.
31. Boyce WE, DiPrima RC. Elementary differential equations and boundary value problems. New York, NY: John Wiley and Sons, Inc, 1992.
32. Fine PEM, Carneiro IAM. Transmissibility and persistence of oral poliovirus vaccine viruses: implications for the Global Poliomyelitis Eradication Initiative. London, United Kingdom: Infectious Disease Epidemiology Unit, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, 1998:1-86.
33. Prevots DR, Ciofi degli Atti ML, Sallabanda A, et al. Outbreak of paralytic poliomyelitis in Albania, 1996: high attack rate among adults and apparent interruption of transmission following nationwide mass vaccination. Clin Infect Dis 1998;26:419-25.
34. Fiore L, Genovese D, Diamanti E, et al. Antigenic and molecular characterization of wild type 1 poliovirus causing outbreaks of poliomyelitis in Albania and neighboring countries in 1996. J Clin Microbiol 1998;36:1912-18.
35. Kew O, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002;296:356-9.
36. Oficina Nacional de Estadística, República Dominicana. Censo nacional de poblacion y vivienda 1993. (In Spanish). Santo Domingo, Dominican Republic: Oficina Nacional de Estadística, 2003.
37. Pan American Health Organization. National polio immunization campaign in the Dominican Republic. EPI Newslett 2000;22:3.
38. Pan American Health Organization. Haiti and the Dominican Republic join efforts to control polio and measles on the Island of Hispaniola. EPI Newslett 2002;24:5-6.
39. Landaverde M, Venczel L, de Quadros C. Brote de poliomielitis en Haití y la República Dominicana debido a un virus derivado de la vacuna antipoliomielítica oral. (In Spanish). Rev Pánam Salud Pública 2001;9:272-4.
40. Shimizu H, Thorley B, Paladin FJ, et al. Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. J Virol 2004;78:13512-21.
41. Yang C, Naguib T, Yang S, et al. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993. J Virol 2003;77:8366-77.
42. Oostvogel P, van Wijngaarden J, van der Avoort HG, et al. Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-3. Lancet 1994;344:665-70.
43. Conyn-Van Spaendonck MA, de Melker HE, Abbink F, et al. Immunity to poliomyelitis in the Netherlands. Am J Epidemiol 2001;153:207-14.
44. Rümke H, Oostvogel PM, van Steenis G, et al. Poliomyelitis in the Netherlands: a review of population immunity and exposure between the epidemics in 1978 and 1992. Epidemiol Infect 1995;115:289-98.
45. Guijt GJ. Beschikbaarheid van het polio vaccin tijdens de epidemie '92-'93. (In Dutch). Infect Bull 1993;4:221-3.
46. Rijksinstituut voor Volksgezondheid en Milieu (RIVM). National kompas volksgezonheid. (In Dutch). Bilthoven, the Netherlands: RIVM, 2003. (http://www.rivm.nl/). (Accessed November 13, 2003).
47. Koopman J. Modeling infection transmission. Annu Rev Public Health 2004;25:303-26.
48. Hull BP, Dowdle WR. Poliovirus surveillance: building the global Polio Laboratory Network. J Infect Dis 1997;175(suppl 1): S113-16.
49. Modlin JF, Halsey NA, Thoms ML, et al. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. J Infect Dis 1997;175(suppl 1):s228-34.
50. Alexander JP Jr, Gary HE Jr, Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J Infect Dis 1997;175(suppl 1):S176-82.
51. Robertson SE. Poliomyelitis. (Immunological basis for immunization series, no. 6). Geneva, Switzerland: World Health Organization, 1993. (Report no. WHO/EPI/Gen/93.16).
52. Gelfland HM, LeBlanc DR, Fox JP, et al. Studies on the development of natural immunity to poliomyelitis in Louisiana. II. Description and analysis of episodes of infection observed in study group households. Am J Hyg 1957;65:367-85.
53. Buonagurio DA, Coleman JW, Patibandla SA, et al. Direct detection of Sabin poliovirus vaccine strains in stool specimens of first-dose vaccinees by a sensitive reverse transcription-PCR method. J Clin Microbiol 1999;37:283-9.
54. Samoilovich E, Roivainen M, Titov LP, et al. Serotype-specific mucosal immune response and subsequent poliovirus replication in vaccinated children. J Med Virol 2003;71:274-80.
55. Kaul D, Ogra P. Mucosal responses to parenteral and mucosal vaccines. Dev Biol Stand 1998;95:141-6.
56. Chen RT, Hausinger S, Dajani AS, et al. Seroprevalence of antibody against poliovirus in inner-city preschool children. JAMA 1996;275:1639-45.
57. Horstmann DM, Paul JR. The incubation period in human poliomyelitis and its implications. JAMA 1947;135:11-14.
58. Population Division, United Nations. World population prospects population database: the 2002 revision population database. New York, NY: United Nations, 2003. (http://esa.un.org/unpp/index.asp?panel=2). (Accessed July 31, 2003).
59. Más Lago P, Bravo JR, Andrus JK, et al. Lesson from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. Bull World Health Organ 1994;72:221-5.
60. Vaccine Assessment and Monitoring Team, Department of Immunization, Vaccines and Biologicals, World Health Organization. Third dose of polio vaccine: reported estimates of Pol3 coverage. Geneva, Switzerland: World Health Organization, 2004. (http://www.who.int/vaccines/globalsummary/timeseries/ tscoveragepol3.htm).
61. Bernier RH. Some observations on poliomyelitis lameness surveys. Rev Infect Dis 1984;6(suppl 2):S371-5.
62. Squarcione S, Germinario C, Iandolo E, et al. Seroimmunity to poliomyelitis in an Albanian immigrant population. Vaccine 1992;10:853-6.
63. Poliomyelitis - Netherlands. MMWR Morb Mortal Wkly Rep 1992;41:775-8.
64. United Nations Children's Fund (UNICEF). The state of the world's children 2003. New York, NY: UNICEF, 2003. (http://www.unicef.org/sowc03/).
65. World Development Indicators Database, World Bank. World Bank list of economies (July 2002). Washington, DC: World Bank, 2002. (www.csirwebistad.org/ pdf/classi.pdf).
66. McBean AM, Thoms ML, Albrecht P, et al. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Am J Epidemiol 1988;128:615-28.
67. Cáceres VM, Sutter RW. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. Clin Infect Dis 2001;33:531-41.